ZogniQ’s ZPL Polarized Light Therapy is Based on Research
We developed Zogniq’s Polarized Light Therapy (ZPL) as the outcome of extensive scientific investigation and deliberate engineering. ZPL is a specialized form of photobiomodulation (PBM) that delivers light with a defined orientation of electromagnetic waves—polarization—engineered to achieve greater consistency and therapeutic reliability.
In designing this technology, our team conducted a comprehensive review of the scientific literature across photobiology, ophthalmology, dermatology, and biophysics. This process involved evaluating the limitations of standard low-level light therapy (LLLT) and identifying areas where polarization could provide measurable improvements. Device parameters, optical configurations, and treatment protocols were established on the basis of published findings, ensuring that the engineering approach was directly aligned with available clinical and preclinical evidence.
The following references illustrate a portion of the research base that informed the development of Zogniq’s ZPL Polarized Light Therapy and support its use as a clinically relevant advancement in photobiomodulation:
Clinical Evidence
ZogniQ Clinical Quick Reference Matrix
| Study | Year | Model/Setting | Light | Key Findings | Parameters |
| Tripodi et al., 2022 | 2022 | Human dermal fibroblasts (in vitro) | Polarized PBM vs non-polarized | ↑ proliferation, ↑ mitochondrial membrane potential, ↓ apoptosis; suggests improved wound-healing potential | 650–850 nm (mixed wavelengths), ~10 J/cm² (reported in paper) |
| Austin et al., 2021 | 2021 | Human dermal fibroblasts (in vitro) | Red light (not polarized) | Transcriptome changes: ECM remodeling, ↑ MMP1, antifibrotic effects | 633 nm, ~10 J/cm² |
| Tripodi et al., 2020 | 2020 | Preclinical review + in vitro | Polarization vs non-polarized | Parallel polarization improved wound closure, collagen organization | Visible/NIR spectrum, fluences 1–10 J/cm² |
| Sund et al., 1999 | 1999 | Cell membrane imaging (mechanistic) | Polarized TIRF | Showed membrane orientation affects polarized field interactions | 488–514 nm excitation |
| Pasek et al., 2024 | 2024 | Clinical RCT pilot, venous leg ulcers (n=40) | Polarized light adjunct vs sham | Greater ulcer area reduction (~33% vs 19%) and pain reduction (~71% vs 38%) | Bioptron lamp, polychromatic polarized 480–3400 nm, 10 min/session, 5×/wk, 10 wks |
| Allam et al., 2025 | 2025 | Review of wound healing studies | Polarized light (broad spectrum) | Summarizes accelerated healing, deeper penetration, cost-effective; more trials needed | Not applicable (review) |
| Lv et al., 2024 | 2024 | Fundamental physics (air–water interface) | Visible light, TM-polarization | Photomolecular effect at interface; polarization alters water interactions | Visible spectrum, interface model |
| Taha et al., 2022 | 2022 | Clinical RCT, diabetic foot ulcers (n=40) | Polarized light (Bioptron) vs control | Ulcer size reduction (51% vs 25%), higher negative cultures (60% vs 15%) | Bioptron lamp, 480–3400 nm polarized, 10 min/session, 3×/wk, 8 wks |
| Feehan et al., 2020 | 2020 | Human monocytes (in vitro) | Polychromatic polarized light | ↓ IL1B, CCL2, NLRP3; ↑ NFKBIA, TLR9 → anti-inflammatory effect | 480–700 nm polarized, ~10 J/cm² |
